People Are Already Taking This Unapproved New Weight-Loss Drug

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...
Healio

Retatrutide confers up to 28.7% weight loss, reduction in knee osteoarthritis pain

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...
TipRanks on MSN

Eli Lilly’s retatrutide study: A new hope for CKD treatment?

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...
BioPharma Dive

Lilly’s three-pronged drug puts obesity field ‘on notice’

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...
PharmExec

Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and ...

2 Predictions for Eli Lilly in 2026

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...
Zacks.com on MSN

Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...